{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:09:18Z","timestamp":1774314558574,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Donafenib is an approved multikinase inhibitor for hepatocellular carcinoma (HCC). However, cutaneous toxicity\u2014particularly hand\u2013foot skin reaction (HFSR)\u2014may necessitate treatment interruption and compromise therapeutic continuity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 58-year-old man with HCC on a cirrhotic background developed abrupt onset of intensely painful plantar erythema with overlying desquamation 10\u201311 days after initiating donafenib. The lesions rapidly progressed, leading to impaired ambulation and were consistent with CTCAE grade 3 HFSR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>Donafenib was immediately discontinued, and the patient received short-term symptomatic management, resulting in prompt improvement of the acral lesions. He was subsequently transitioned to lenvatinib, which was well tolerated without recurrence of high-grade skin toxicity. The patient maintained clinical stability and was able to continue systemic anticancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the importance of early detection and accurate grading of HFSR, timely treatment interruption, and mechanism-informed switching to an alternative tyrosine kinase inhibitor such as lenvatinib. It also underscores key differences in toxicity profiles between donafenib\u2014associated with VEGFR\/RAF-related cutaneous injury\u2014and lenvatinib, which is more commonly linked to hypertension, diarrhea, and appetite or weight changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1728098","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:16:04Z","timestamp":1766034964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Donafenib intolerance in hepatocellular carcinoma: severe hand\u2013foot skin reaction and successful switch to lenvatinib \u2013 a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linglin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinuo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/cancers16010051","article-title":"Systemic treatment in intermediate stage (barcelona clinic liver cancer-B) hepatocellular carcinoma","volume":"16","author":"Karagiannakis","year":"2023","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.12688\/f1000research.145493.2","article-title":"Hepatocellular carcinoma: Advances in systemic therapies","volume":"13","author":"Wu","year":"2024","journal-title":"F1000research"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/life15010072","article-title":"Cabozantinib cutaneous toxicity-comprehensive review","volume":"15","author":"Tutunaru CV,\u00a0Alexandru","year":"2025","journal-title":"Life (basel Switz)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12885-023-10864-9","article-title":"Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial","volume":"23","author":"Nishizawa","year":"2023","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.trsl.2022.02.004","article-title":"Nitric oxide in multikinase inhibitor-induced hand-foot skin reaction","volume":"245","author":"Chen","year":"2022","journal-title":"Transl Res: J Lab Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1425","article-title":"Outcomes of acitretin treatment for refractory multikinase inhibitor-induced hand-foot skin reaction","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","article-title":"Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management","volume":"17","author":"Chanprapaph","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.08.001","article-title":"Small-molecule-based targeted therapy in liver cancer","volume":"32","author":"Ming","year":"2024","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01603-0","article-title":"Donafenib: first approval","volume":"81","author":"Keam","year":"2021","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review","volume":"10","author":"Cappuyns S,\u00a0Corbett","year":"2024","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1358\/dot.2023.59.2.3507751","article-title":"Donafenib in hepatocellular carcinoma","volume":"59","author":"Chen","year":"2023","journal-title":"Drugs Today (barc Spain: 1998)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2024.09.061","article-title":"Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for unresectable advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"32","author":"Jiang","year":"2025","journal-title":"Acad Radiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"96267","DOI":"10.4251\/wjgo.v17.i1.96267","article-title":"Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma","volume":"17","author":"Wu","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-304","article-title":"Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01119-0","article-title":"Liver cirrhosis affects the pharmacokinetics of the six substrates of the basel phenotyping cocktail differently","volume":"61","author":"Duthaler","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"114914","DOI":"10.1016\/j.bcp.2022.114914","article-title":"Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition","volume":"197","author":"Hasan Alshammari","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2402","article-title":"Atezolizumab plus bevacizumab versus lenvatinib for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"64","author":"Lu","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"B22","article-title":"Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer","volume":"13","author":"E","year":"2024","journal-title":"Eur Thyroid J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"17562848221140662","DOI":"10.1177\/17562848221140662","article-title":"First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States","volume":"15","author":"Sun","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2079498","article-title":"Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma","volume":"22","author":"Meng","year":"2022","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.869960","article-title":"Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis","volume":"10","author":"Zhao","year":"2022","journal-title":"Front Public Health"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02185-3","article-title":"Cost-effectiveness of donafenib as first-line treatment of unresectable hepatocellular carcinoma in China","volume":"39","author":"Guan","year":"2022","journal-title":"Adv Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.058","article-title":"Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials","volume":"174","author":"Fulgenzi","year":"2022","journal-title":"Eur J Cancer (oxf Engl: 1990)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.771045","article-title":"First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis of randomized clinical trials","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i19.2415","article-title":"Selection of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials","volume":"27","author":"Han","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy","volume":"40","author":"Deutsch","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.4345","article-title":"Recovering from stevens-johnson syndrome and toxic epidermal necrolysis","author":"Martin-Pozo","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2016.55","article-title":"Abdominal skin rash after TACE due to non-target embolization of hepatic falciform artery","volume":"3","author":"Nagpal","year":"2016","journal-title":"ACG Case Rep J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100673","article-title":"DRESS syndrome: a literature review and treatment algorithm","volume":"16","author":"Calle","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/ijd.IJD_579_17","article-title":"Causality or relatedness assessment in adverse drug reaction and its relevance in dermatology","volume":"63","author":"Pande","year":"2018","journal-title":"Indian J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1689122","article-title":"Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management","volume":"12","author":"Ai","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037563","article-title":"Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma","volume":"7","author":"Mir","year":"2012","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1958674","article-title":"Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma","volume":"14","author":"Catalano","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91442-8_13","article-title":"Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFR\u03b1, KIT and RET","volume":"211","author":"Zsch\u00e4bitz","year":"2018","journal-title":"Recent Results Cancer Res Fortschr Krebsforsch Prog Dans Rech Sur Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1517","article-title":"Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models","volume":"7","author":"Matsuki","year":"2018","journal-title":"Cancer Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1728098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:16:05Z","timestamp":1766034965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1728098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":42,"alternative-id":["10.3389\/fonc.2025.1728098"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1728098","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1728098"}}